

REFERENCES

1. **Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (2002)** Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. *J Clin Microbiol* 40:1656–1659.

2. **Alavian SM , Mehdi Hosseini-Moghaddam SM, Rahnavardi M(2007).** Hepatitis C among Hemodialysis Patients: A Review on Epidemiologic, Diagnostic, and Therapeutic Features. *Hepatitis Monthly*.(3): 153-162.

3. **Abacioglu YH, Bacaksiz F, Bahar IH et al.(2000)** Molecular evidence of nosocomial transmission of hepatitis C virus in a haemodialysis unit. *Eur J Clin Microbiol Infect Dis* 19: 182–186.

4. **Agnello V(2000):** Mixed cryoglobulinemia and other extrahepatic manifestations of HCV infection, in Liang TJ, Hoofnagle JH (eds): *Hepatitis C*. San Diego, CA, Academic , pp 295-313.

5. **Ahmetagic S, Muminhodzic K, Cickusic E, Stojic V, Petrovic J, Tihic N(2006).** Hepatitis C infection in risk groups. *Bosn J Basic Med Sci* 6: 13-7.

6. **Albuquerque AC, Coelho MR, Lopes EP, Lemos MF, Moreira RC(2005).** Prevalence and risk factors of hepatitis C virus infection in hemodialysis patients from one center in Recife, Brazil. *Mem Inst Oswaldo Cruz* 100: 467-70.

7. **Alfurayh O, Sabeel A, Hamid M, et al.(2000)** hand contamination with hepatitis C virus in staff looking after hepatitis C-positive haemodialysis patients. *Am J Nephrol* Mar-Apr;20(2):103-6.

8. **Almroth G, Ekermo B, Mansson AS, Svensson G, Widell A (2002).** Detection and prevention of hepatitis C in dialysis patients and renal transplant recipients. A long-term follow up (1989-January 1997). *J Intern Med* 251: 119-28.

9. **Alter MJ, Margolis HS, Krawczynski K, et al.(1994):** The natural history of community-acquired hepatitis C in the United States. *The Sentinel*

Counting Chronic non-A, non-B Hepatitis Study Team. Am J Kidney Dis Nov;24(5):795-801.

10. **Alter MJ.(2002)** Prevention of spread of hepatitis C. Hepatology 36: S93-S98.

11. **Alter MJ, Kuhnert WL, Finelli L (2003)** Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for disease control and prevention. MMWR recomm rep 52:1–13, 15; quiz CE11–14.

12. **Alter MJ(2007).** Epidemiology of hepatitis C virus infection. World J Gastroenterol May 7; 13(17): 2436-2441.

13. **Amiri ZM, Shakib AJ, Toorchi M(2005).** Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J 11: 372-6.

14. **Angelico M, Morosetti M, Passalacqua S, Chiappini MG, Botta S, Ombres D, Splendiani G, Casciani CU(2000).** Low levels of hepatitis C virus RNA in blood of infected patients under maintenance haemodialysis with high-biocompatibility high-per-meability filters. Dig Liver Dis 32: 724-8.

15. **Angelini C, Badalamenti S, Lunghi G, Sampietro M, Finazzi S, Ponticelli C, Graziani G(2002).** Evidence against hepatitis C virus trapping in dialysis membranes (letter). Nephrol Dial Transplant 17: 317-8.

16. **Annicchiarico BE, Siciliano M(2004):** Pegylated interferon- alpha 1b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther 20: 17.

17. **Ansaldi F, Bruzzzone B, De Florentiis D, Marasso P, Gota F , Mofferdin A, Campello Crovari P, Icardi G.(2003)** . an outbreak of hepatitis C virus infection in a haemodialysis unit: Molecular evidence of patient to patient transmission. Ann Ig . Oct ;15(5):685-91.

18. **Aoyagi K, Iida K, Ohue C, Matsunaga Y, Tanaka E, Kiyosawa K, et al(2001).** Performance of a conventional enzyme immunoassay for hepatitis C virus core antigen in the early phases of hepatitis C infection. Clin Lab 47: 119-27.

19. **Arenas MD , Sanchez-Paya J , Munos C, Egae JJ , Martin F, Gil MT, Sarro F.(2001).** Nosocomial transmission of the hepatitis C virus in haemodialysis: monitor personnel , or both. *Nefrologia*; Oct;21 (5):476-84.
20. **Artan R, Akcam M, Yilmaz A, Kocacik D(2005).** Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients. *J Chemother.* 17:651–655.
21. **Asselah T, Boyer N, Guimont MC, Cazales-Hatem D, Nahon KM, Daikha H, Vidaud D, Martinot M, Vidaud M, Degott C, Valla D, Marcellin P.(2003).** Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. *Gut.* Nov; 52(11):1638-43.
22. **Aucella F, Vigilante M, Valente GL, Stallone C(2000).** Systematic monitor disinfection is effective in limiting HCV spread in hemodialysis. *Blood Purif* 18: 110-4.
23. **Badalamenti S, Catania A, Lunghi G, Covini G, Bredi E, Brancaccio D, et al(2003).** Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus positive patients: only coincidental phenomena? *Am J Kidney Dis* 42: 143-50.
24. **Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M(2000)** Renal disease associated with hepatitis C infection after kidney and liver transplantation. *Transplantation* 70:255-261.
25. **Barrera JM (2000).** Diagnostic tests for hepatitis C virus infection. *Nephrol Dial Transplant* 15(suppl 8):15-18.
26. **Barril G, Bartolome J , Traver JA , et al .(2000)** Autoclaving eliminates hepatitis C virus from a haemodialysis monitor contaminated artificially . *J Med Virol* Feb;60(2):139-43.
27. **Barril G, Traver JA.(2003)** Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: Effect of time, initiating HCV prevalence studies and adoption of isolation measures. *Antivir Res.* 60: 129–134.
28. **Barril G, Quiroga JA, Sanz P, Rodriguez-Salvanes F, Selgas R, CarrenoV(2004):** Pegylated interferon alfa2a kinetics during experimental

haemodialysis: impact of permeability and pore size of dialysers. *Aliment Pharmacol Ther* 20: 37–44.

29. **Bedossa P, Dargere D and Paradis V (2003):** Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 38:1449.

30. **Bergman S, Accortt N, Turner A, et al. (2005):** hepatitis C infection acquired pre-ESRD. *Am J Kidney Dis* Apr;45(4):684-9.

31. **Berthous F, Abramowicz D, Bradley B, Ekberg H, Frei U, Morales J, Olgaard K, Paul Leiden L, Ponticelli C (2000)** Evaluation ,selection and preparation of the potential transplant recipient in section 1: european best practice guidelines for renal transplantation (part 1). *Nephrol Dial Transplant*;15(suppl 7): 3-38.

32. **Blumberg A, Zehnder C, Burckhardt JJ (1995).** Prevention of hepatitis C infection in haemodialysis units. A prospective study. *Nephrol Dial Transplant* 10: 230–233.

33. **Booth J C, Grady J O and Neuberger J (2001):** Clinical guidelines on the management of hepatitis C. *Gut* 49 (suppl 1): I1-I21.

34. **Borawski J, Naumnik B, Mysliwiec M (2005)** Liver disease vs. systemic inflammation in haemodialysis patients. *Nephrol Dial Transplant* 20:1277–1278.

35. **Bouzgarrou N, Fodha I, Othman SB, Achour A, Grattard F, Trabelsi A, et al (2005).** Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. *J Med Virol* 77: 502-8.

36. **Boyacioglu S, Gur G, Yilmaz U, Korkmaz M, Demirhan B, Bilezikci B, et al (2004).** Investigation of possible clinical and laboratory predictors of liver fibrosis in hemodialysis patients infected with hepatitis C virus. *Transplant Proc* 36: 50-2.

37. **Boyer N and Marcellin P (2000):** Pathogenesis ,diagnosis and management of hepatitis C .*J Hepatol* 32(1 suppl):98-112.

38. **Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R(2006):** Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. *J Viral Hepat* 13:316–321.
39. **Bruchfeld A, Lindahl K, Schvarcz R, Stahle L(2002):** Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population based pharmacokinetic analysis. *Ther DrugMonit* 24:701–708.
40. **Bruchfeld A, Stahle L, Andersson J, Schvarz R(2001):** Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. *J Viral Hepat* 8:287–292.
41. **Bruguera M, Saiz JC, Franco S, Gimenez-Bareones M, Tapias JM, Fabregas S, Vega R, Camps N, Dominguez A And Salleras L (2002):** outbreak of nosocomial Hepatitis C infection resolved by genetic analysis of HCV RNA. *J Clin Microbiol.*, Nov;1(11): 4363-4366.
42. **Bunnapradist S, Fabrizi F, Vierling J, Martin P, Moudgil A, Kamil E, Jordan S(2002):**Hepatitis C therapy with long-term remission after renal transplantation. *Int J ArtifOrgans* 25:1189–1193.
43. **Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH(2005).** A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. *Transfusion* 45: 254-264
44. **Buturovic-Ponikvar J(2003).** Renal replacement therapy in Slovenia: annual report 2001. *Nephrol Dial Transplant* 18: v53-5.
45. **Calabrese G, Vagelli G, Guaschino R, et al.(1991):** transmission of anti-HCV within the household of haemodialysis patients. *Lancet* Dec 7;338(8780):1466.
46. **Caramelo C, Navas S, Alberola ML, et al. (1994):** evidence against transmission of hepatitis C virus through haemodialysis ultra filtrate and peritoneal fluid . *Nephron* 66(4):470-3.
47. **Castell J and Gutierrez G(2005).** Outbreak of 18 cases of hepatitis C in a hemodialysis unit. *Gac Sanit* 19: 214–220.

48. **Castera L, Constant A, Bernard Ph, Ledinghen V, Couzigou P.(2006).** Lifestyle changes and believes regarding disease severity in patients with chronic hepatitis C. *Journal Of Viral Hepatitis* . 13(7):482-7.
49. **CDC,(2001):**Recommendations for preventing transmission of infections among chronic hemodialysis patients. *MMWR Recomm Rep* 50: 1-43.
50. **CDC,(2003):** GUIDANCE for environmental infection control in health care facilities. *MMWR* 6, 2003/52; 1-42.
51. **Cendoroglo Netro M, Draibe SA ,Silva AE , et al.(1995):** Incidence of another risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: Evidence for environmental transmission. *Nephrol Dial Transplant* 10(2):240-6.
52. **Cheney CP, Chopra S, Graham C.(2000).** Hepatitis C infectious Disease Clinics Of North American vol.14,No.3.
53. **Chlabicz S, Flisiak R, Grzeszczuk A, Kovalczuk O, Prokopowicz D, Chyczewski L(2006).** Known and probable risk factors for hepatitis C infection: A case series in north-eastern Poland. *World J Gastroenterol*. 12: 141–145.
54. **Choo QL,Kuo G,Weiner AJ, Overby LR, Bradley DW, Houghton M(1989)** Isolation of a c DNA clone derived from ablood bornenon-A,non – Bviral hepatitis genome. *Science* 244 :359-362.
55. **Comanor L, Anderson F, Ghany M, Perrillo R, Heathcote EJ, Sherlock C, Zitron I, Hendricks D, Gordon SC (2001)** Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. *Am J Gastroenterol* 96:2968–2972.
56. **Comanor L, Elkin C, Leung K, Krajden M, Kronquist K, Nicolas K, Horansky E, deMedina M, Kittichai P, Sablon E, Ziermann R, Sherlock C (2003)** Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcription-mediated amplification in conjunction with the line probe assay. *J Clin Virol* 28:14–26.

57. **Cotler SJ, Diaz G, Gundlapalli S, Jakate S, Chawla A, Mital D, et al(2002).** Characteristics of hepatitis C in renal transplant candidates. *J Clin Gastroenterol* 35: 191-5.
58. **Courouce AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, et al(2000).** Efficacy of HCV core antigen detection during the preseroconversion period. *Transfusion* 40: 1198-202.
59. **Covic A, Maftai ID, Mardare NG, et al(2006):** Analysis of safety and efficacy of pegylated interferon α -2a in hepatitis C virus-positive hemodialysis patients: results from a large, multicenter audit. *J Nephrol* 19: 794– 801.
60. **Cruzado JM, Carrera M, Torras J, Grinyo JM(2001):** Hepatitis C virus infection and de novo glomerular lesions in renal allografts. *Am J Transplant* 1:171– 178.
61. **Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo JM(2003):** Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts byHCV RNA clearance. *Am J Transplant* 3:357–360.
62. **D’Amico G(1998):** Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis. *Kidney Int* 54: 650-671.
63. **Davis GI and Lau JY(1997).** Factors predictive of a beneficial response to therapy of hepatitis C. *Hepatology*. 3(Suppl 1):122–127.
64. **Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM(2002).**Prevalence of Hepatitis C virus antibodies among different populations of relative and attributable risk. *Saudi Med J* 23: 1356-60.
65. **De Vita S, De Re V, Gasparotto D, et al(2000):** Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: Clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. *Arthritis Rheum* 43:94-102.
66. **Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman SR, Monterroso E, Williams I, Garfein RS(2003).** Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. *Am J Epidemiol* 157: 467-471.

67. **Deuffic-Burban S, Mohamed MK, Laouze B, et al.(2006):**Expected increase in hepatitis C- related mortality in Egypt due to pre-2000 infections. *Hepatol . Mar ;44(3):455-461.*
68. **Diouf ML, Diouf B, Niang A, Ka EH, Pouye A, Seck A, et al(2000).**Prevalence of hepatitis B and C viruses in a chronic hemodialysis center in Dakar. *Dakar Med 45: 1-4.*
69. **Dos Santos JP,Loureiro A, Periera BJ, et al.(1996):** Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units . *Nephrol Dial Transplant Oct;11(10):2017-22.*
70. **Du Bois DB, Gretch D, Dela Rosa C, et al.(1994):** Quantitation of hepatitis C viral RNA in sera of haemodialysis patients: gender-related differences in viral load. *Am J Kidney Dis Nov;24(5):795-801.*
71. **Eckardt KU(1996).** Erythropoietin production in liver and kidneys. *Curr Opin Nephrol Hypertens. 5:28–34.*
72. **El-Amin HH, Osman EM, Mekki MO, Abdelraheem MB, Ismail MO, Yousif ME, et al(2007).** Hepatitis C virus infection in hemodialysis patients in Sudan: two centers' report. *Saudi J Kidney Dis Transpl 18: 101-6.*
73. **El-Sadawy M, Ragab H, El-Toukhy H, et al.(2004):** hepatitis C virus infection at Sharkia Governorate , Egypt : seroprevalence and associated risk factors. *J-Egypt-Soc-Parasitol. Apr; 34(1 Suppl):367-84.*
74. **El-Serag HB, Hampel H, Yeh C, Rabeneck L(2002):** Extrahepatic manifestations of hepatitis C among United States. male veterans. *Hepatology 36:1439-1445.*
75. **Ennibi K,Bechade D, Rabhi M, Goutant G, Toloune F, Desrame J, Archane MI, Algaryres JP. (2003).** Non Hodgkin's lymphoma and hepatitis C virus infection. *Rev Med Interne. Jul; 24(7):452-8.*
76. **Espinosa M, Martn-Malo A, Ojeda R, Santamara R, Soriano S, Aguera M, Aljama P (2004)** Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. *Am J Kidney Dis 43:685–689.*

77. **Espinosa M, Martin-Malo A, Alvarez de lara M, Aljama P(2001):** Risk of death and liver cirrhosis in anti-HCV –positive long-term haemodialysis patients. *Nephrol Dial Transplant* ;16:1669-1674.
78. **Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S, et al(1998).** Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. *Nephron* 80: 428-33.
79. **Fabrizi F, Martin P, Dixit V, Brezina M, Russell J, Conrad A, et al (1999).** Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. *Am J Nephrol* 19: 383-8.
80. **Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Vinson S, Mousa M, Gitnick G(2000).** Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. *Am J Kidney Dis* 35: 122-9.
81. **Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, et al(2001).** Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. *Am J Kidney Dis* 38: 1009-15.
82. **Fabrizi F, Poordad FF, Martin P(2002) :** Hepatitis C Infection and the Patient With End-Stage Renal Disease. *Hepatology* 36:3-10.
83. **Fabrizi F, Bunnapradist S, Lunghi G, and Martin P.(2003):** Kinetics of hepatitis C virus load during hemodialysis: novel perspectives. *J NEPHROL* 16: 467-475.
84. **Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P(2003):** Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. *Aliment Pharmacol Ther* 18:1071–1081.
85. **Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G(2004).** Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. *Aliment Pharmacol Ther* 20: 1271-7.
86. **Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G(2005):** Posttransplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. *Am J Transplant* 5:2433–2440.

87. **Fabrizi F, De Vecchi AF, Como G, Lunghi G, Martin P(2005).** De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. *Aliment Pharmacol Ther* 21: 861-9.
88. **Fabrizi F, Lunghi G, Dixit V, Martin P(2006):** Meta-analysis: antiviral therapy of hepatitis C virus-related liver disease in renal transplant patients. *Aliment Pharmacol Ther* 24:1413–1422.
89. **Fabrizi F, Lunghi G, Ganeshan SV, Martin P, and Messa P.(2007):** Hepatitis C Virus Infection and the Dialysis Patient. *Seminars in Dialysis—Vol 20, No 5 (September–October)* pp. 416–422.
90. **Fanning L, Kenny E, Sheehan M, Cannon B, Whelton M, O’Connell J, Collins JK, Shanahan F(1999).** Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. *Hepatology* 29: 904-7.
91. **Favero MS, Tokars JI, Arduino MJ, Alter MJ(1999).** Nosocomial infections associated with hemodialysis. In: Mayhall CG, ed. *Hospital epidemiology and infection control*, 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 897--917.
92. **Finelli L, Miller JT, Tokars JI et al(2002).** National surveillance of dialysis associated diseases in the United States, 2002. *Semin Dial* 18: 52–61.
93. **Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al(2004).** Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. *Kidney Int* 65: 2335-42.
94. **Foster GR(2004):** Review article: pegylated interferons: chemical and clinical differences. *Aliment Pharmacol Ther* 20: 825–830.
95. **Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. (2000):** The role of parenteral antischistosomal therapy in the spread of HCV in Egypt . *lancet* ;355:887-891.

96. **Fried MW, Shiffman ML, Reddy KR, et al(2002):** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. *N Engl J Med* 347: 975–982.
97. **Froio N, Nicastrì E, Comandini U, et al(2003).** Contamination by hepatitis B and C viruses in the dialysis setting. *Am J Kidney Dis.* 42:546–550.
98. **Furusyo N, Hayashi J, Ariyama I, Sawayama Y, Etoh Y, Shigematsu M, Kashiwagi S(2000).** Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. *Am J Gastroenterol* 95: 490-6.
99. **Furusyo N, Hayashi J, Kanamoto-Tanaka Y, Ariyama I, Etoh Y, Shigematsu M, et al(2000).** Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10- year study. *Dig Dis Sci* 45: 2221-8.
100. **Furusyo N, Hayashi J, Kakuda K, Ariyama I, Kanamoto-Tanaka Y, Shimizu C, et al(2001).** Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. *Am J Gastroenterol* 96: 1592-600.
101. **Garcia-Valdescasas J, Bernal MC Cerezo S, et al.(1993).** Strategies reduce the transmission of HCV infection in haemodialysis(HD) unit (abstract). *J Am Soc Nephrol* 4:347.
102. **Gordon AS, Naughton BA(1980).** Mechanisms of extrarenal EPO (Ep) production. *Exp Hematol.* 8(Suppl 8): 14–28.
103. **Gramlich T, Mullen KD, O’Shea R, Carey WD, Ferguson R (2004)** Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. *J Clin Gastroenterol* 38:705–709.
104. **Grethe DR, Gernsma F, Monazahian M, et al. (2000):** Molecular epidemiology of an outbreak of HCV in a haemodialysis unit: direct sequencing of HCV-HVRI as an appropriate tool for phylogenetic analysis. *J Med Virol* Feb;60(2):152-8.
105. **Gursoy M, Guvener N, Koksall R, Karavelioglu D, Baysal C, Ozdemir N, Boyacioglu S, Bilgin N, Erdal R(2006):** Impact of HCV

infection on development of posttransplantation diabetes mellitus in renal allograft recipients. *Transplant Proc* 32:561–562.

106. **Halfon P, Khiri H, Feryn JM, Sahada C, Chanas M, Ouzan D(1998).** Prospective virological follow-up of hepatitis C infection in a haemodialysis unit. *J Viral Hepat* 5: 115-21.

107. **Halfon P , Roubicek C , Gerolami V,Quentin Y, Khiri H , Pepe G , Berland Y.(2002).** Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable regic 1 sequences to trace an out break of HCV in an autodialysis unit . *J Clin Microbiol Apr ;40(4):1541-5.*

108. **Hanuka N, Sikuler E, Tovbin D, Neville L, Nussbaum O, Mostoslavsky M, Orgel M, Yaari A, Manor S, Dagan S, Hilzenrat N, Shemer-Avni Y (2004)** Hepatitis C virus infection in dialysis and chronic liver patients: viraemia dependent anti-E2-antibody response.*J Med Virol* 73:529–535.

109. **Hauri AM, Armstrong GL, Hutin YJ(2004).** The global burden of disease attributable to contaminated injections given in health care settings. *Int J STD AIDS* 15: 7-16.

110. **Hermine O, Lefrere F, Bronowicki JP, et al(2002):** Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. *N Engl J Med* 347:89-94.

111. **Hino K and Okita K. (2004).** Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. *J Antimicrob Chemother Jan;53(1);19-22.*

112. **Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE(2002).** Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. *Gut* 51: 429-33.

113. **Hladik W, Kataaha P, Mermin J, Purdy M, Otekat G, Lackritz E, Alter MJ, Downing R(2006).** Prevalence and screening costs of hepatitis C virus among Ugandan blood donors. *Trop Med Int Health* 11: 951-954.

114. **Hmaied F, Ben Mamou M, Saune-Sandres K et al(2006).** Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. *J Med Virol* 78: 185–191.
115. **Hoofnagle JH.(1997).** Hepatitis C: The clinical spectrum of the disease . *Hepatology* 26-135 .
116. **Hosseini-Moghaddam SM, Keyvani H, Kasiri H, Kazemeyni SM, Basiri A, Aghel N, et al(2006).** Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran--a multicenter study. *J Med Virol* 78: 569- 73.
117. **Huang CC(2002)** Hepatitis infection in hemodialysis patients. *Nephrology* ;7(3):101.
118. **Hubmann R, Zazgornik J, Gabriel C , et al. (1995):** hepatitis C virus does it penetrate the haemodialysis membrane ? PCR analysis of haemodialysis ultra filtrate and whole blood . *Nephrol Dial Transplant* 10(4):541-2.
119. **Hwang LY, Kramer JR, Troisi C, Bull L, Grimes CZ, Lyster R, Alter MJ(2006).** Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. *Hepatology* 44: 341-351.
120. **Ifudu O, Uribarri J, Rajwani I, Vlacich V, Reydel K, Delosreyes G, FriedmanE(2002)** Low hematocrit may connote a malnutrition–inflammation syndrome in hemodialysis patients. *Dialysis Transplant* 31:845–878.
121. **Iwasaki Y, Esumi M, Hosokawa N, Yanai M, Kawano K(2000).**Occasional infection of hepatitis C virus occurring inhaemodialysis units identified by serial monitoring of the virus infection. *J Hosp Infect* 45: 54-61.
122. **Izopet J, Rostaing L, Sanders K, Cisterne J-M,Pasquier C,et al. (2000):** longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. *The Journal Of Infectious Disease*; 181:852-858.

123. **Jadoul M, Cornu C, van Ypersele de Strihou C(1993).** Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. *Kidney Int* 44: 1322–1326.
124. **Jadoul M, Cornu C, Van Y ,et al.(1998).** Universal precautions prevent hepatitis C virus transmission: a 54 month follow up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc(UCL) Collaborative Group. *Ideny Int Apr*;53(4):1022-5.
125. **Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C,Krajewska M, et al(2004).** The changing epidemiology of hepatitisC virus (HCV) infection in haemodialysis: European multicentre study. *Nephrol Dial Transplant* 19: 904-9.
126. **Jayasekera H.(2001).** hepatitis C virus: overview of clinical and technical prospectives. *EDNTA –ERCA J. Sep(3):*125-8.
127. **Jeffers LJ ,Perez GO, Duncan R, et al.(1990):** hepatitis C infection in two urban haemodialysis units. *Kidney Int Aug*;38(2):320-2.
128. **Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD (2003)** Malnutrition–inflammation complex syndrome in dialysis patients: causes and consequences. *Am J Kidney Dis* 42:864–881.
129. **Kalantar-Zadeh K, Miller LG, Daar ES.(2005)** Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. *Am J Kidney Dis* 46: 290-300.
130. **Kalantar-Zadeh K, McAllister CJ, Miller LG (2005)** Clinical characteristics and mortality in hepatitis C positive haemodialysis patients: a population based study. *Nephrol Dial Transplant* 20:1662–1669.
131. **Kalantar-Zadeh K, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S, Kilpatrick RD (2006)** Hepatitis C virus and death risk in hemodialysis patients. *Am J Kid Dis* 47:B1–B18 (abstract #73, NKF Spring Clinical Meetings April 19–23, 2006, Chicago, IL), 2006 [abstract].
132. **Kalantar-Zadeh K, Daar ES, Eysselein VE, Miller LG(2007):** Hepatitis C inflection in dialysis patients: a link to poor clinical outcome?. *Int Urol Nephrol* 39:247–259.

133. **Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjerdtson DW, et al.(2007)** Hepatitis C virus and death risk in hemodialysis patients. *J Am Soc Nephrol* 18: 1584-93.
134. **Kamar N, Toupance O, BuchlerM, Sandres-Saune K, Izopet J, Durand D, Rostaing L(2003):** Evidence that clearance of hepatitis C virus RNA after alphainterferon therapy in dialysis patients is sustained after renal transplantation. *J Am Soc Nephrol* 14:2092–2098.
135. **Kasprazak A, Zabel M, Bichzysko W, Wysocki J, Admek A, Spachacz R, Surdyk-Zasada J.(2004).** Expression of cytokines (TNF-alpha, IL-1 alpha and IL-2)in chronic hepatitis C: comparative hybridocytochemical and immunocytochemical study in children and adult patients. *J Histochem Cytochem* 52, (1):29-38.
136. **Katsoulidou A, Paraskevis D, Kalapothaki V et al(1999).** Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis. *Nephrol Dial Transplant* 14: 1188–1194.
137. **KDIGO Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease(2008).** *Kidney International* 73 (Suppl 109), 510-599.
138. **Kelley VA, Everett-Kitchens J, Brannon LE, Connor K, Martinez EJ, Pearson TC, et al(2002).** Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. *Transplantation* 74: 1473-5.
139. **Kes P, Basic-Jukic N(2007):** Hepatitis C in Dialysed Patients – What Is the Current Optimal Treatment?. *Kidney Blood Press Res* 30:156–161.
140. **Khaja MN, Madhavi C, Thippavazzula R, Nafeesa F, Habib AM, Habibullah CM, et al(2006).** High prevalence of hepatitis C virus infection and genotype distribution among general population, blood donors and risk groups. *Infect Genet Evol* 6: 198-204.
141. **Khan N, Aswad S, Shidban H, Aghajani M, Mendez R, Comanor L (2004)** Improved detection of HCV infection in hemodialysis patients using a new HCV RNA qualitative assay: experience of a transplant center. *J Clin Virol* 30:175–182.

142. **Khurana A, Nickel AE, Narayanan M, Foulks CJ.(2008)** Effect of hepatitis C infection on anemia in hemodialysis patients *Hemodialysis International* 12:94–99.
143. **Kiyosawa K, Sodeyama T, Tanaka E, et al. (1991):** hepatitis C in hospital employees with needle stick injuries. *Ann Intern Med* Sep 1;115(5):367-9.
144. **Kokoglu OF, Ucmak H, Hosoglu S, et al(2006):** Efficacy and tolerability of pegylated interferon alpha-2a in hemodialysis patients with chronic hepatitis C. *J Gastroenterol Hepatol* 21: 575–580.
145. **Koksal I(2006):** Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C. *J Gastroenterol Hepatol* 21: 575–580.
146. **Kokubo S, Horii T, Yonekawa O et al(2002).** A phylogenetic-tree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. *J Viral Hepat* 9: 450–454.
147. **Kondili LA, Genovese D, Argentini C et al(2006).** Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. *Eur J Clin Microbiol Infect Dis* 25: 527–531.
148. **Krajden M, Ziermann R, Khan A, Mak A, Leung K, Hendricks D, Comanor L (2002)** Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. *J Clin Microbiol* 40:2903–2907.
149. **Lauer GM and Walker BD(2001):** Hepatitis C virus infection *N Engl J med*;345(1):41-52.
150. **La Torre G, Miel L, Southern Lazio Collaborative Group,et al(2006).** Correlates of HCV seropositivity among familial contacts of HCV positive patients. *BMC Public Health*. 6:237–245.
151. **Le Pogam S, Le Chapois D, Christen R et al(1998).** Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. *J Clin Microbiol* 36: 3040–3043.

152. **Lindahl K, Stahle L, Bruchfeld A, Schvarcz R(2005):** High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. *Hepatology* 41:275–279.
153. **Lombardi M, Cerrai T, Dattolo P, et al.(1995):** Is the dialysis membrane a safe barrier against HCV infection ?.*Nephrol Dial Transplant* 10(4)578.
154. **Luzar B, Ferlan-Marolt V, Brinovec V, Lesnicar G, Klopčič U, Poljak M(2003).** Does end-stage kidney failure influence hepatitis C progression in hemodialysis patients? *Hepatogastroenterology* 50: 157-60.
155. **Mahmoud IM, Sobh MA, El-Habashi AF, Sally ST, El-BazM, El-Sawy E, Ghoneim MA(2005):** Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. *Nephron Clin Pract* 100:c133–c139.
156. **Manns MP, McHutchison JG, Gordon SC, et al(2001).** Peginterferon alfa-2b plus ribavirin compared with interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. *Lancet.* 358:958–965.
157. **Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, et al(2000).** Histopathological features of hepatitis C in renal transplant candidates. *Transplantation* 69:1479-1484.
158. **Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, Alter MJ(2005).** Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J Infect Dis* 192: 1880-1889.
159. **McHutchison JG and Gordon SC(1998),** for the Hepatitis Interventional Therapy Group, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med.* 339:1485– 1492.
160. **McMurray RW (1997).** hepatitis C virus infection and autoimmunity . *Semin Arthritis Rheum*;26:689.
161. **Mendez-Sanchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M(2004).** Prevalence of hepatitis C virus infection

among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. *J Clin Microbiol* 42: 4321-2.

162. **Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH (2003).** Hepatitis C and renal disease: An update. *Am J Kidney Dis.* 42:631–657.

163. **Miller LG, Kalantar-Zadeh K, Daar ES (2005)** Diagnostic discordance for hepatitis C virus infection in hemodialysis: correlations with clinical and laboratory features [Reply to Letter]. *Am J Kid Dis* DOI: 10.1053/j.ajkd.2005.07.045. Cited 4 October 2005.

164. **Mitsui T, Iwano K, Masuko K, et al. (1992):** hepatitis C infection in medical personal after needle stick accident . *Hepatology* Nov ;16(5):1109-14.

165. **Mitwalli T, Iwano K, Masuko K, et al.(1992):** Hepatitis C in chronic renal failure patients. *Am J Nephrol*:12(5):288-91.

166. **Mizuno M, Higuchi T, Yanai M, Kanmatsuse K, Esumi M (2002).** Dialysis-membrane-dependent reduction and adsorption of circulating hepatitis C virus during hemodialysis. *Nephron* 91: 235-42.

167. **Mohamed MK(2004).** Epidemiology of HCV in Egypt 2004.The Afro-Arab Liver Journal, vol 3, No2,(July), pp 41-52.

168. **Mousa DH, Abdalia AH, Al-Shoail G, Sulaiman MH, Al-Hawas FA, Al-Khader AA(2004):** Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. *Transplant Proc* 36:1831–1834.

169. **Murphy EL, Bryzman SM, Glynn SA,et al.(2000):** risk factors for hepatitis C virus infection in United States blood donors . *NHLBI Retrovirus Epidemiology Donor Study (REDS).* *Hepatology* Mar;31(3):756-62.

170. **Murray JM, Law MG, Gao Z, Kaldor JM(2003).** The impact of behavioural changes on the prevalence of human immuno-deficiency virus and hepatitis C among injecting drug users. *Int J Epidemiol* 32: 708-714.

171. **Nakayama E, Akiba T, Marumo F, Sato C(2000).** Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. *J Am Soc Nephrol* 11: 1896-902.

172. **Nascimento MM, Suliman ME, Bruchfeld A, et al(2004).** The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. *Nephrol Dial Transplant.* 19:3112–3116.
173. **National Kidney Foundation(1997).** Dialysis outcomes quality initiative. Clinical practice guidelines. *Am J Kidney Dis* 30(Suppl 3):S137--S240. Available on the Internet at <<http://www.kidney.org>>.
174. **Ndimbie OK, Kingsley LA, Nedjar S, Rinaldo CR (1996)** Hepatitis C virus infection in a male homosexual cohort: risk factor analysis. *Genitourin Med* 72:213–216.
175. **Noiri E , Nakao A ,Oya A, et al .(2001):** hepatitis C virus in blood and dialysate in haemodialysis. *Am J Kidney Dis* Jan;37(1):38-42.
176. **Ocak S, Duran N, Kaya H, Emir I(2006).** Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis. *Int J Clin Pract* 60: 670-4.
177. **Olmer M, Bouchouareb D, Zandotti C, de Micco P, de Lamballerie X(1997).** Transmission of the hepatitis C virus in a hemodialysis unit: Evidence for nosocomial infection. *Clin Nephrol.* 47:263–270.
178. **Omata M and Yoshida H(2004).** Prevention and treatment of hepatocellular carcinoma. *Liver Transpl. (Suppl)* 2: 111-4.
179. **Pawlak K, Pawlak D, Mysliwiec M (2004)** Hepatitis intensified oxidative stress, MIP-1beta and RANTES plasma levels in uraemic patients. *Cytokine* 28:197– 204.
180. **Pawlotsky JM(2006).** Therapy of hepatitis C: From empiricism to eradication. *Hepatology.* 43(Suppl 1):207–220.
181. **Periera BJ and Levely AS (1997):** Hepatitis C virus infection in dialysis and renal transplantation . *Kidney Int* Apr;51(4):981-99.

182. **Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS (1998)** Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The new England organ bank hepatitis C study group. *Kidney Int* 53:1374–1381.
183. **Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP(2006).** The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 45: 529-538.
184. **Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, et al(2001).** Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. *Am J Kidney Dis* 37: 1004-10.
185. **Pickering MC, Cook HT, Warren J, et al (2002):** Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. *Nat.Genet* 31:424-428.
186. **Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Brechot C(1995):** Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. *Kidney Int* 47:1412–1418.
187. **Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J, Serfaty L, Bedossa P, Brechot C(2004).** Reversibility of hepatitis C virus-related cirrhosis. *HumPathol* 35:107–112.
188. **Pouteil-Noble C, Maiza H, Dijoud F, MacGregor B(2000):** Glomerular disease associated with hepatitis C virus infection in native kidneys. *Nephrol Dial Transplant* 15:S28-S33, (suppl 8).
189. **Pybus OG, Drummond AJ, Nakono T, et al .(2003):** the epidemiology and iatrogenic transmission of hepatitis C virus in Egypt : a Bayesian coalescence approach. *Mol-Biol-Evol.* Mar ;20(3):381-7.
190. **Rais-Jalali G and Khajehdehi P(1999):** anti-HCV seropositivity among haemodialysis patients of Iranian origin. *Nephrol Dial Transplant* Aug;14(8):2055-6.
191. **Rampino T, Arbustini E, Gregorini M, Guallini P, Libetta C, Maggio M, et al(1999).** Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. *Kidney Int* 56: 2286-91.

192. **Rangel MC, Coronado VG, Euler GL, Strikas RA(2000).** Vaccine recommendations for patients on chronic dialysis. *Semin Dial* 13:101—7.
193. **Regev A, Berho M, Jeffers LJ, et al.(2002):** sampling error at intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 97:2614.
194. **Rigopoulou EI, Stefanidis I, Liaskos C, Zervou EK, Rizos C, Mina P, et al(2005).** HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. *J Clin Virol* 34: 81-5.
195. **Rivanera D, Lilli D, Lorino G, Pirozzi V, Cannulla V, Dicuonzo G, et al(1993).** Detection of antibodies to hepatitis C virus in dialysis patients. *Eur J Epidemiol* 9: 55-8.
196. **Roberts EA and Yeung L(2002).** Maternal-infant transmission of hepatitis C virus infection. *Hepatology* 36: S106-S113
197. **Rodés J and Sánchez Tapias JM (2000):**Hepatitis C. *Nephrol Dial Transplant*;15(suppl 8):2-11 .
198. **Russo MW, Ghalib R, Sigal S, Joshi V(2006).** Randomized trial of pegylated interferon α -2b monotherapy in hemodialysis patients with chronic hepatitis C. *Nephrol Dial Transplant*. 21:437–443.
199. **Saab S, Brezina M, Gitnick G, Martin P, Yee HF, Jr(2001).** Hepatitis C screening strategies in hemodialysis patients. *Am J Kidney Dis* 38: 91-7.
200. **Saab S, Martin P, Brezina M, Gitnick G, Yee HF, Jr(2001).** Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. *Am J Kidney Dis* 37: 308- 15.
201. **Sabry A , E-Agroudy A, Sheashaa H , El-husseini A, Taha N, Elbaz M, Sobh M.(2005):** HCV associated glomerulopathy in Egyptian patients: Clinicopathological analysis. *Virology* 334: 10–16.
202. **Sahin I, Arabaci F, Sahin HA, et al(2003).** Does hepatitis C virus infection increase hematocrit and hemoglobin levels in hemodialyzed patients? *Clin Nephrol*. 60:401–404.

203. **Salama G, Rostaing L, Sandres K, Izopet J(2000).** Hepatitis C virus infection in French hemodialysis units: a multicenter study. *J Med Virol* 61: 44-51.
204. **Sartor C, Brunet P, Simon S et al(2004).** Transmission of hepatitis C virus between hemodialysis patients sharing the same machine. *Infect Control Hosp Epidemiol* 25: 609–611.
205. **Savey A, Simon F, Izopet J et al(2005).** A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. *Infect Control Hosp Epidemiol* 26: 752–760.
206. **Saxena AK, Panhotra BR, Sundaram DS, Naguib M, Venkateshappa CK, Uzzaman W, et al(2003).** Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. *Am J Infect Control* 31: 26-33.
207. **Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, et al(2000).** The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. *J Infect Dis* 182: 1291-9.
208. **Schroeter M, Zoellner B, Polywka S et al(2005).** Prolonged time until seroconversion among hemodialysis patients: the need for HCV PCR. *Intervirology* 48: 213–215.
209. **Scott JD and Gretch DR(2007).** Molecular diagnostics of hepatitis C virus infection: a systematic review. *JAMA* 297: 724-32.
210. **Seeff LB(2002).** Natural history of chronic hepatitis C. *Hepatology* 36 (suppl 1): S35-46.
211. **Shamshirsaz AA, Kamgar M, Bekheirnia MR et al(2004).** The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. *BMC Nephrol* 5: 13.
212. **Shan Y, Lambrecht RW, Bonkovsky HL(2005).** Association of hepatitis C virus infection with serum iron status: Analysis of data from the third national health and nutrition examination survey. *Clin Infect Dis.* 40:834–841.

213. **Shepard CW, Finelli L, Fiore AE, Bell BP(2005).** Epidemiology of hepatitis B and hepatitis B virus infection in United States children. *Pediatr Infect Dis J* 24: 755-760.
214. **Shiffman ML.(2003).** Natural history and risk factors for progression of hepatitis C virus disease and development of Hepatocellular Cancer before liver transplantation. *Liver Transpl.* 9(11):S14-20.
215. **Simjanovska L.J., Porcu K., Amitov V., et al(2004).** Reverse transcriptase/polymerase chain reaction analyses of hemodialysis ultrafiltrates and sera of hepatitis C virus positive patients. *Int J Artif Organs* 27 : 35-9.
216. **Simmonds P, Albert A, Alter HJ, Bonino F, et al.(1994 a):** a proposed system for the nomenclature of hepatitis C virus viral genotypes. *Hepatology* ; 19:1321-1324.
217. **Simmonds P, Smith Dp, Mc Omish F, et al. (1994b):** identification of genotypes of hepatitis C virus by sequence comparisons in core, E1 and N55 region. *J Gen Virol*;75: 1053-1061.
218. **Simmonds P (1995)** variability of hepatitis C virus. *Hepatology* ;21:570-583.
219. **Simmonds P, Mallor J, Sakuldamrongpaninch T, et al. (1996):** evolutionary analysis of variants of hepatitis C virus found in South East Asia the comparison with classification based upon sequence similarity. *J Gen Virol*;7: 3013-302.
220. **Simon P, Meyrier A, Tanquerel T, Ang KS(1980).** Improvement of anemia in haemodialysed patients after viral or toxic hepatic cytolysis. *Br Med J.* 280:892–894.
221. **Smith DD, Basaras M, Frost S, Haydon D, Cuceanu N, Prescott, et al.(2000).** Phylogenetic analysis of GBV-C/hepatitis G virus. *Journal of General Virology*; 81:769-780.
222. **Sporea I, Popescu A, Sirli R, et al(2006):** Pegylated interferon alpha-2a treatment for chronic hepatitis C in patients on chronic haemodialysis. *World J Gastroenterol* 12: 4191–4194.

223. **Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ (1998)** Risk of death among chronic dialysis patients infected with hepatitis C virus. *Am J Kidney Dis* 32:629–634.
224. **Stenvinkel P, Chung SH, Heimbürger O, Lindholm B (2001)** Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. *Perit Dial Int* 21(Suppl 3):S157–S162.
225. **Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, Mills SA, et al(1999).** Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. *Am J Gastroenterol* 94;3576-3582.
226. **Strader DB, Wright T, Thomas DL, Seeff LB(2004).** Diagnosis, management, and treatment of hepatitis C. *Hepatology* 39: 1147-71.
227. **Stragier A. (2003):** dialyzer reuse : the debate continues. *Nephrol news issues* .17,(12):97.
228. **Stuyver L, Claeys H, Wyseur A, et al.(1996):** Hepatitis C virus in haemodialysis unit: molecular evidence for nosocomial transmission. *Kidney Int Mar*;49(3):889-95.
229. **Sullivan Dg, Kim SS, Wilson JJ, et al. (2001):** Investigating Hepatitis C virus heterogeneity in a high prevalence setting using heteroduplex tracking analysis. *J Virol Methods Jul*;96(1):5-16.
230. **Sulowicz W, Radziszewski A, Chowaniec E.(2007):** Hepatitis C virus infection in dialysis patients. *Hemodialysis International* 11:286–295.
231. **Sypsa V, Psychogiou M, Katsoulidou A, Skoutelis G, Moutafis S, Hadjiconstantinou V, et al(2005).** Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. *Am J Kidney Dis* 45: 334-43.
232. **Takada S, Gotoh Y, Hayashi S, et al.(1996):** Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese. *J Nat Cancer Inst*;88:742-6.

233. **Taneda S, Segerer S, Hudkins KL, et al(2001):** Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice. *Am J Pathol* 159:2355-2369.
234. **Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H Shiratori Y, Omata M. (2004).** Hepatitis C virus core protein up regulates transforming growth factor-beta: 1 transcription. *J Med Virol* Jan;72(1):52-9.
235. **Taskapan H, Oymak O, Dogukan A, Utas C(2001).** Patient to patient transmission of hepatitis C virus in hemodialysis units. *Clin Nephrol.* 55:477–481.
236. **Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M(2005):** Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. *Nephrol Dial Transplant* 20: 991–993.
237. **The Canadian Society Of Nephrology(2005)** Recommendations From The Ad Hoc Committee On The Prevention Of Transmission Of Blood- Borne Pathogens In Hemodialysis Patients., March 2005 available on the internet at www.csnsn.ca.
238. **Thio CL, Goedert JJ, Mosbrugger T, Vlahov D, Strathdee SA, O'Brien SJ, Astemborski J, Thomas DL (2004)** An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. *Genes Immun* 5:294–300.
239. **Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, Monterroso ER, Garfein RS(2002).** Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. *Am J Epidemiol* 155: 645-653.
240. **Tokars JI ,Miller ER, Alter MJ, et al .(1998):** national surveillance of dialysis associated diseases in the United States , 1995 . *ASAIO J* Jan-Feb;44(1):98-107.
241. **Tokars JI, Arduino MJ, Alter MJ(2001).** Infection control in haemodialysis units. *Infect Dis Clin North Am*, Sep; 15 (3): 797-812.
242. **Toussiort E, Le Huede G , Mougin C, Balblance JC, Bettinger D, Wendling D.(2002)** . presence of hepatitis C virus RNA in the salivary glands of patients with Sjogren's syndrome and hepatitis C virus infection. *J .Rheumatol* Nov;29(11):2382-5.

243. **Umlauft F, Gruenewald K, Weiss G, Kessler H, Urbanek M, Haun M, Santner B, Koenig P, Keeffe EB (1997)** Patterns of hepatitis C viremia in patients receiving hemodialysis. *Am J Gastroenterol* 92:73–78.
244. **Urbanek P, Tesar V, Prochazkova-Francisci E, Lachmanova J, Marecek Z, Svobodnik A(2004):** Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon- α .Treatment of hepatitis C. *Blood Purif* 22: 344–350.
245. **Vagelli G, Calabrese G, Guaschino R, et al.(1992):** effect of HCV-patients isolation on HCV infection incidence in a dialysis unit. *Nephrol Dial Transplant* 7(10):1070.
246. **Valtuille R, Moretto H, Lef L, Rendo P, Fernandez JL (2002).**Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. *Clin Nephrol* 57: 371-5.
247. **Vanderborght BO, Rouzere C, Ginuino CF, Martens G, Van Herverswyn H, Yoshida CF. (1995).** High prevalence of hepatitis C virus infection among Brazillian haemodialysis patients in Rio de Janeiro : one-year follow-up study. *Rev Inst Med Trop Sao Paulo*;37(1):75-79.
248. **Wreghitt TG(1999).** Blood-borne virus infections in dialysis units--a review. *Rev Med Virol* 9: 101-9.
249. **Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O'Shea R, Carey WD, Ferguson R (2004)** Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. *J Clin Gastroenterol* 38:705–709.
250. **Zacks SL and Fried MW (2001)** Hepatitis B and C and renal failure. *Infect Dis Clin North Am* 15:877–899.
251. **Zeuzem S, Scheuerman EH, Waschk D, et al(1996).** Phylogenetic analysis of hepatitis C virus isolates from hemodialysis patients. *Kidney Int.* 49:896–902.